In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate

The objective was to evaluate the transdermal delivery of the 5-HT1B/1D agonist, sumatriptan from an iontophoretic patch system, in vivo. Initial in vitro experiments were conducted to optimize formulation parameters prior to iontophoretic delivery in Yorkshire swine. It was found in vitro that increasing drug load in the patch from 9.7 to 39 mg had no statistically significant effect on cumulative delivery (cf. 305.6 ± 172.4 vs. 389.4 ± 80.4 μg cm−2, respectively). However, for a given drug load (39 mg) increasing formulation pH from pH 4.7 to 6.8 significantly increased the cumulative amount of sumatriptan delivered across the skin (389.4 ± 80.4 vs. 652.4 ± 94.2 μg cm−2). A biphasic current profile comprising intensities of 1.8 mA from t = 0 to t = 180 min and 0.8 mA from t = 181 min to t = 360 min was used for the in vivo experiments. Drug levels in the blood were 13.7 ± 4.5 and 53.6 ± 10.2 ng ml−1 at the 30 and 60 min time-points, rising to 90–100 ng ml−1 during the 90–180 min time-period. The in vivo results show that the pharmacokinetics following transdermal iontophoretic delivery are comparable to those after oral, nasal or rectal administration, but do not match those upon subcutaneous injection.